Success Metrics

Active Trials
5(63%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_1
2
25%
Ph phase_2
5
63%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Recruiting4
Not yet recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 25 (62.5%)
Phase 31 (12.5%)

Trials by Status

not_yet_recruiting338%
active_not_recruiting113%
recruiting450%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_1

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

NCT07655622
not_yet_recruitingphase_2

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

NCT07549061
recruitingphase_2

Vebreltinib for Advanced or Metastatic CCS

NCT07153887
recruitingphase_1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

NCT06343064
recruitingphase_2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

NCT06574347
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07655622Phase 1

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Recruiting
NCT07549061Phase 2

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

Not Yet Recruiting
NCT07153887Phase 2

Vebreltinib for Advanced or Metastatic CCS

Recruiting
NCT06343064Phase 1

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Recruiting
NCT06574347Phase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Recruiting
NCT06970782Phase 3

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Not Yet Recruiting
NCT06827145Phase 2

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Active Not Recruiting
NCT06644313Phase 2

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Not Yet Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8